Article
Biocon Biologics set to reap biosimilar insulin glargine opportunity in US
Rating:
0.0
Views:
62
Likes:
1
Library:
1
Drugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit growth in the next several quarters, primarily from the US market.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value